News

Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity
Viking Therapeutics (VKTX 1.70%) is developing VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The company ...
Barchart on MSN45m
What You Need to Know Ahead of L3Harris’ Earnings Release
Valued at roughly $47.4 billion by market cap, L3Harris Technologies, Inc. (LHX) is reshaping the defense landscape with ...